"Designing Growth Strategies is in our DNA"
The human body undertakes a series of complex mechanims in order to stop bleeding and these mechanisms include the creation of blood clot. In the creation of blood clot, requires factor VII, a type of protein. Factor VII acts by binding itself to tissue factor at the site of injury to the blood vessel in order to generate thrombin, which is critical for the formation of fibrin. Congenital factor VII deficiency refers to a disorder where there are low levels of factor VII in the blood. Moreover, the increasing awareness and R&D have also aided the expansion of congenital factor VII deficiency treatment industry. As of 2019, Novo Nordisk A/S product offering of NovoSeven (coagulation Factor VIIa, recombinant) is the only product offering approved by the FDA for the treatment of congenital factor VII deficiency.
Global congenital factor VII deficiency treatment market growth is being driven by the increase in awareness for rare bleeding disorders and anticipated product launches for bleeding disorders. Furthermore, the rise in the efficiency of approved product offerings, leading to an increased adoption of advanced therapeutics is expected to further drive the global congenital factor VII deficiency treatment market growth during the forecast period. According to the Novo Nordisk A/S, the prevalence of congenital factor VII deficiency is estimated to affect 1 in 500,000 patients with male and female patients equally affected.
Key Market Driver -
Increasing awareness and ongoing R&D in congenital factor VII deficiency
Key Market Restraint -
Lower prevalence in patients globally may hinder interest in the development of new pipeline candidates
On the flip side, the extremely rare nature of the disorder and the underreporting and non-diagnosis of patients are the factors that can restrain the growth in global congenital factor VII deficiency treatment market.
The major companies covered in the global congenital factor VII deficiency treatment market report include Novo Nordisk A/S, Biogen, CSL, and other players.
As per the current congenital factor VII deficiency treatment market trends, recombinant factor VIIa (rFVIIa) among the treatment segment are anticipated to register a higher market share in the global congenital factor VII deficiency treatment market owing to recombinant factor VIIa (rFVIIa) being one of the most primary and critical treatment options.
The global congenital factor VII deficiency treatment market has been segmented into North America, Europe, Asia Pacific, and rest of the world. The congenital factor VII deficiency treatment market is anticipated to expand in North America during the forecast years owing to the fast adoption to advanced therapeutics and increased awareness regarding rare bleeding disorders. In Europe, the prevalence of congenital factor VII deficiency is estimated to be 1 in 300,000 and increased awareness is anticipated to augment the congenital factor VII deficiency treatment market by the end of 2026.
To gain extensive insights into the market, Request for Customization
In Asia Pacific, the evolving healthcare infrastructure, increasing disposable incomes and increasing awareness regarding bleeding disorders are anticipated to fuel the congenital factor VII deficiency treatment market growth during the forecast period. Additionally, congenital factor VII deficiency treatment market in the rest of the world such as Latin America and the Middle East & Africa is in the nascent stage; however, unmet needs for bleeding disorders is expected to drive the market growth in this region.
By Distribution Channel
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry